Idiopathic Pruritus Ani and Acute Perianal Dermatitis
This article reviews the etiologies, pathophysiology, clinical evaluation, and treatment of idiopathic pruritus ani and perianal dermatitis. It underscores a practical approach to each of these common proctologic conditions. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text
Atopic dermatitis (AD) is associated with increased systemic inflammation and cardiovascular risk. While previous studies showed increased inflammatory proteins in the blood of AD patients, detailed comparison among AD patients of different ages is unavailable.
Filaggrin is a major epidermal protein that has been shown to be a key player in the pathogenesis of AD and allergic disease. While filaggrin is a significant genetic risk factor for AD, it is also an important disease modifier in AD. Patients with filaggrin related AD and asthma have more frequent hospital admissions and long-term medication costs. Atopic dermatitis patients with FLG mutations are more frequently affected by reduced health related quality of life when compared to AD patients with wild-type FLG.
Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, N...
ConclusionsEvidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality.
Authors: Maloney NJ, Tegtmeyer K, Zhao J, Worswick S Abstract Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different dermatologic conditions, including allergic c...
Authors: Sheriff T, Lin MJ, Dubin D, Khorasani H Abstract Cannabis is increasingly being used world-wide to treat a variety of dermatological conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 countries in Europe. The authors reviewed the literature on the pharmacology and use of cannabinoids in treating a variety of skin conditions including acne, atopic dermatitis, psoriasis, skin cancer, pruritus, and pain. Cannabinoids have demonstrated anti-inflammatory, antipruritic, anti-ageing, and antimalignancy properties by various mechanisms including interacting with the newly ...
Flea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats.
ConclusionsThe present study allowed the identification of different protein areas specific to these studied groups. The protein spots of interest were identified by UHPLC-MS/MS. It has been possible to establish a link between a specific symptomatology and the newly identified responsible allergens.
Chandra Sekhar Sirka, Kananbala Sahu, Swetalina Pradhan, Arpita Nibedita RoutIndian Journal of Dermatology, Venereology, and Leprology 2019 85(6):623-626
PMID: 31603528 [PubMed - as supplied by publisher]